Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018039430) RADIOFLUORINATED CARBOXIMIDAMIDES AS IDO TARGETING PET TRACER FOR CANCER IMAGING
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/039430 International Application No.: PCT/US2017/048370
Publication Date: 01.03.2018 International Filing Date: 24.08.2017
IPC:
A61K 31/41 (2006.01) ,A61K 31/166 (2006.01) ,A61K 31/4245 (2006.01) ,C07D 271/02 (2006.01) ,C07D 271/08 (2006.01) ,C07D 273/02 (2006.01)
[IPC code unknown for A61K 31/41][IPC code unknown for A61K 31/166][IPC code unknown for A61K 31/4245][IPC code unknown for C07D 271/02][IPC code unknown for C07D 271/08][IPC code unknown for C07D 273/02]
Applicants:
H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. [US/US]; 12902 Magnolia Drive Tampa, Florida 33612-9497, US
Inventors:
TIAN, Haibin; US
GILLIES, Robert; US
Agent:
CURFMAN, Christopher L.; US
HALL, Miles E.; US
Priority Data:
62/378,87824.08.2016US
Title (EN) RADIOFLUORINATED CARBOXIMIDAMIDES AS IDO TARGETING PET TRACER FOR CANCER IMAGING
(FR) CARBOXIMIDAMIDES RADIOFLUORÉS EN TANT QUE TRACEURS POUR LA TEP CIBLANT L'IDO, DESTINÉS À L'IMAGERIE DU CANCER
Abstract:
(EN) Radiofluorinated carboximidamides are disclosed as selective IDO enzyme radioligands and generate specific binding in accordance with IDO expression in vitro. MicroPET experiments indicate [18F]IDO49 specifically accumulate in IDO-expressing tumors which confirmed by Western blot and IHC analysis supported. Using Hela tumor bearing models with IFN-γ treatment confirmed that [18F]IDO49 accumulation in the IFN- γ treatment tumor mouse. These results can have implications that [18F]IDO49 has substantial potential as an imaging agent that targets IDO in tumors.
(FR) L'invention concerne des carboximidamides radiofluorés en tant que radioligands sélectifs de l'enzyme IDO, qui créent une liaison spécifique en fonction de l'expression de l'IDO in vitro. Des expériences de microTEP indiquent que la [18F]IDO49 s'accumule spécifiquement dans des tumeurs exprimant l'IDO, confirmant ce qui était étayé par l'analyse par Western blot et par immunohistochimie. L'utilisation de modèles porteurs de tumeurs issues de cellules Hela et recevant un traitement par l'IFN-γ a confirmé cette accumulation de la [18F]IDO49 dans la souris porteuse de tumeur recevant un traitement par l'IFN-γ. L'implication de ces résultats seraient que la [18F]IDO49 a un potentiel substantiel en tant qu'agent d'imagerie ciblant l'IDO dans des tumeurs.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)